(TERN) Terns Pharmaceuticals - Ratings and Ratios
Oncology, Obesity, Cancer, Leukemia, MASH
TERN EPS (Earnings per Share)
TERN Revenue
Description: TERN Terns Pharmaceuticals
Terns Pharmaceuticals Inc (NASDAQ:TERN) is a clinical-stage biopharmaceutical company focused on developing innovative small-molecule treatments for oncology and obesity. The companys pipeline includes several promising candidates, such as TERN-701, a tyrosine kinase inhibitor for chronic myeloid leukemia, TERN-501, a thyroid hormone receptor beta agonist for metabolic dysfunction-associated steatohepatitis (MASH), and TERN-601, a Glucagon-Like Peptide-1 receptor agonist for obesity.
From a financial perspective, TERN has a market capitalization of $349.35M USD, indicating a relatively small-cap company with potential for growth. The absence of a P/E ratio suggests that the company is not yet profitable, which is consistent with its clinical-stage status. The Return on Equity (RoE) of -28.81% indicates significant investment in research and development, which is typical for biopharmaceutical companies.
To further evaluate TERNs potential, we can consider key performance indicators (KPIs) such as cash runway, R&D expenses as a percentage of revenue, and pipeline progress. A longer cash runway would indicate a lower risk of capital constraints, while a high R&D expense ratio would suggest a strong commitment to innovation. The progress of TERNs pipeline candidates, particularly TERN-701 and TERN-501, will be crucial in determining the companys future prospects.
Additionally, we can analyze the companys valuation using metrics such as Enterprise Value (EV) to Market Cap ratio, and compare it to industry peers. A relative valuation analysis would provide insights into whether TERN is undervalued or overvalued compared to its competitors. Furthermore, monitoring news and updates from the company, such as clinical trial results, regulatory approvals, and partnerships, will be essential in assessing TERNs potential for future growth.
TERN Stock Overview
| Market Cap in USD | 639m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2021-02-05 |
TERN Stock Ratings
| Growth Rating | -12.6% |
| Fundamental | 22.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -35.2% |
| Analyst Rating | 4.33 of 5 |
TERN Dividends
Currently no dividends paidTERN Growth Ratios
| Growth Correlation 3m | 96.4% |
| Growth Correlation 12m | -32.9% |
| Growth Correlation 5y | -36.7% |
| CAGR 5y | 9.44% |
| CAGR/Max DD 3y | 0.11 |
| CAGR/Mean DD 3y | 0.19 |
| Sharpe Ratio 12m | -0.06 |
| Alpha | 0.21 |
| Beta | 0.058 |
| Volatility | 74.46% |
| Current Volume | 811.5k |
| Average Volume 20d | 1014.1k |
| Stop Loss | 6.9 (-6.8%) |
| Signal | 0.03 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-91.7m TTM) > 0 and > 6% of Revenue (6% = -5.50m TTM) |
| FCFTA -0.22 (>2.0%) and ΔFCFTA 7.35pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -334.0% (prev 16.6k%; Δ -16.9kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.23 (>3.0%) and CFO -74.4m > Net Income -91.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 24.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (91.6m) change vs 12m ago 22.99% (target <= -2.0% for YES) |
| Gross Margin 100.1% (prev 30.56%; Δ 69.56pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover -33.24% (prev 0.57%; Δ -33.82pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -33.47
| (A) 0.96 = (Total Current Assets 319.0m - Total Current Liabilities 12.9m) / Total Assets 320.4m |
| (B) -1.47 = Retained Earnings (Balance) -469.5m / Total Assets 320.4m |
| warn (B) unusual magnitude: -1.47 — check mapping/units |
| (C) -0.37 = EBIT TTM -102.5m / Avg Total Assets 275.6m |
| (D) -30.92 = Book Value of Equity -469.5m / Total Liabilities 15.2m |
| Total Rating: -33.47 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 22.08
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -21.48% = -5.0 |
| 3. FCF Margin -76.45% = -7.50 |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda -0.03 = -2.50 |
| 6. ROIC - WACC (= -30.56)% = -12.50 |
| 7. RoE -27.35% = -2.50 |
| 8. Rev. Trend -4.37% = -0.33 |
| 9. EPS Trend 58.19% = 2.91 |
What is the price of TERN shares?
Over the past week, the price has changed by -0.94%, over one month by +9.47%, over three months by +89.74% and over the past year by -23.16%.
Is Terns Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TERN is around 7.34 USD . This means that TERN is currently overvalued and has a potential downside of -0.81%.
Is TERN a buy, sell or hold?
- Strong Buy: 5
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TERN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.8 | 140.7% |
| Analysts Target Price | 17.8 | 140.7% |
| ValueRay Target Price | 8 | 8.2% |
Last update: 2025-09-18 04:42
TERN Fundamental Data Overview
CCE Cash And Equivalents = 315.4m USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -91.7m + Cost of Revenue 108.0k = -91.6m USD
P/S = 302.636
P/B = 2.093
Beta = -0.049
Revenue TTM = -91.6m USD
EBIT TTM = -102.5m USD
EBITDA TTM = -101.8m USD
Long Term Debt = 2.27m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 444.0k USD (from shortTermDebt, last quarter)
Debt = 2.72m USD (Calculated: Short Term 444.0k + Long Term 2.27m)
Net Debt = -144.8m USD (from netDebt column, last quarter)
Enterprise Value = 326.1m USD (638.8m + Debt 2.72m - CCE 315.4m)
Interest Coverage Ratio = unknown (Ebit TTM -102.5m / Interest Expense TTM 0.0)
FCF Yield = -21.48% (FCF TTM -70.1m / Enterprise Value 326.1m)
FCF Margin = -76.45% (FCF TTM -70.1m / Revenue TTM -91.6m)
Net Margin = -100.1% (Net Income TTM -91.7m / Revenue TTM -91.6m)
Gross Margin = -100.1% ((Revenue TTM -91.6m - Cost of Revenue TTM 108.0k) / Revenue TTM)
Tobins Q-Ratio = -0.69 (set to none) (Enterprise Value 326.1m / Book Value Of Equity -469.5m)
Interest Expense / Debt = 94.59% (Interest Expense 2.57m / Debt 2.72m)
Taxrate = 21.0% (US default)
NOPAT = -102.5m (EBIT -102.5m, no tax applied on loss)
Current Ratio = 24.70 (Total Current Assets 319.0m / Total Current Liabilities 12.9m)
Debt / Equity = 0.01 (Debt 2.72m / last Quarter total Stockholder Equity 305.2m)
Debt / EBITDA = -0.03 (Net Debt -144.8m / EBITDA -101.8m)
Debt / FCF = -0.04 (Debt 2.72m / FCF TTM -70.1m)
Total Stockholder Equity = 335.4m (last 4 quarters mean)
RoA = -28.63% (Net Income -91.7m, Total Assets 320.4m )
RoE = -27.35% (Net Income TTM -91.7m / Total Stockholder Equity 335.4m)
RoCE = -30.36% (Ebit -102.5m / (Equity 335.4m + L.T.Debt 2.27m))
RoIC = -30.56% (NOPAT -102.5m / Invested Capital 335.4m)
WACC = unknown (E(638.8m)/V(641.5m) * Re(6.15%)) + (D(2.72m)/V(641.5m) * Rd(none%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 8.19%
Discount Rate = 6.15% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -70.1m)
EPS Correlation: 58.19 | EPS CAGR: 105.1% | SUE: 0.53 | # QB: 0
Revenue Correlation: -4.37 | Revenue CAGR: 0.0% | SUE: N/A | # QB: None
Additional Sources for TERN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle